A Genome-wide Association Study of Chemotherapy-induced Alopecia in Breast Cancer Patients

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2013 Sep 13

PMID 24025145

Citations 13

Authors

Suyoun Chung

Siew-Kee Low

Hitoshi Zembutsu

Atsushi Takahashi

Michiaki Kubo

Mitsunori Sasa

Yusuke Nakamura

Affiliations

Soon will be listed here.

Abstract

Introduction: Chemotherapy-induced alopecia is one of the most common adverse events caused by conventional cytotoxic chemotherapy, yet there has been very little progress in the prevention or treatment of this side effect. Although this is not a life-threatening event, alopecia is very psychologically difficult for many women to manage. In order to improve the quality of life for these women, it is important to elucidate the molecular mechanisms of chemotherapy-induced alopecia and develop ways to effectively prevent and/or treat it. To identify the genetic risk factors associated with chemotherapy-induced alopecia, we conducted a genome-wide association study (GWAS) using DNA samples from breast cancer patients who were treated with chemotherapy.

Methods: We performed a case-control association study of 303 individuals who developed grade 2 alopecia, and compared them with 880 breast cancer patients who did not show hair loss after being treated with conventional chemotherapy. In addition, we separately analyzed a subset of patients who received specific combination therapies by GWASs and applied the weighted genetic risk scoring (wGRS) system to investigate the cumulative effects of the associated SNPs.

Results: We identified an SNP significantly associated with drug-induced grade 2 alopecia (rs3820706 in CACNB4 (calcium channel voltage-dependent subunit beta 4) on 2q23, P = 8.13 × 10(-9), OR = 3.71) and detected several SNPs that showed some suggestive associations by subgroup analyses. We also classified patients into four groups on the basis of wGRS analysis and found that patients who classified in the highest risk group showed 443 times higher risk of antimicrotubule agents-induced alopecia than the lowest risk group.

Conclusions: Our study suggests several associated genes and should shed some light on the molecular mechanism of alopecia in chemotherapy-treated breast cancer patients and hopefully will contribute to development of interventions that will improve the quality of life (QOL) of cancer patients.

Citing Articles

Quesada S, Guichard A, Fiteni F Cancers (Basel). 2021; 13(21).

PMID: 34771716 PMC: 8583126. DOI: 10.3390/cancers13215556.

Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women With Breast Cancer.

Nunez-Torres R, Martin M, Garcia-Saenz J, Rodrigo-Faus M, Del Monte-Millan M, Tejera-Perez H JAMA Dermatol. 2020; 156(9):987-991.

PMID: 32756886 PMC: 7407317. DOI: 10.1001/jamadermatol.2020.1867.

CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia.

Purba T, Ngandu K, Brunken L, Smart E, Mitchell E, Hassan N EMBO Mol Med. 2019; 11(10):e11031.

PMID: 31512803 PMC: 6783643. DOI: 10.15252/emmm.201911031.

Use of big data in drug development for precision medicine: an update.

Qian T, Zhu S, Hoshida Y Expert Rev Precis Med Drug Dev. 2019; 4(3):189-200.

PMID: 31286058 PMC: 6613936. DOI: 10.1080/23808993.2019.1617632.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin S, Chua K, Ho C, Mulkey F, Jiang C, Mushiroda T Clin Pharmacol Ther. 2018; 105(3):738-745.

PMID: 30260474 PMC: 6379108. DOI: 10.1002/cpt.1241.

References

Granai C, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H . The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol. 1991; 12(2):129-32. View

Li G, Deng X . Functional ion channels in stem cells. World J Stem Cells. 2011; 3(3):19-24. PMC: 3097936. DOI: 10.4252/wjsc.v3.i3.19. View

McGarvey E, Baum L, Pinkerton R, Rogers L . Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2002; 9(6):283-9. DOI: 10.1046/j.1523-5394.2001.96007.x. View

Duvic M, Lemak N, Valero V, Hymes S, Farmer K, Hortobagyi G . A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996; 35(1):74-8. DOI: 10.1016/S0190-9622(96)90500-9. View

Wang J, Lu Z, Au J . Protection against chemotherapy-induced alopecia. Pharm Res. 2006; 23(11):2505-14. DOI: 10.1007/s11095-006-9105-3. View

Manev H, Manev R . 5-Lipoxygenase (ALOX5) and FLAP (ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med Hypotheses. 2005; 66(3):501-3. DOI: 10.1016/j.mehy.2005.09.031. View

Young P, Boussadia O, Halfter H, Grose R, Berger P, Leone D . E-cadherin controls adherens junctions in the epidermis and the renewal of hair follicles. EMBO J. 2003; 22(21):5723-33. PMC: 275417. DOI: 10.1093/emboj/cdg560. View

Rodriguez R, Machiavelli M, Leone B, Romero A, Cuevas M, Langhi M . Minoxidil (Mx) as a prophylaxis of doxorubicin--induced alopecia. Ann Oncol. 1994; 5(8):769-70. DOI: 10.1093/oxfordjournals.annonc.a058986. View

Yamada M, Ishii N, Asao H, Murata K, Kanazawa C, Sasaki H . Signal-transducing adaptor molecules STAM1 and STAM2 are required for T-cell development and survival. Mol Cell Biol. 2002; 22(24):8648-58. PMC: 139881. DOI: 10.1128/MCB.22.24.8648-8658.2002. View

10.

Paus R, Haslam I, Sharov A, Botchkarev V . Pathobiology of chemotherapy-induced hair loss. Lancet Oncol. 2013; 14(2):e50-9. DOI: 10.1016/S1470-2045(12)70553-3. View

11.

Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y . A high-throughput SNP typing system for genome-wide association studies. J Hum Genet. 2001; 46(8):471-7. DOI: 10.1007/s100380170047. View

12.

Chon S, Champion R, Geddes E, Rashid R . Chemotherapy-induced alopecia. J Am Acad Dermatol. 2011; 67(1):e37-47. DOI: 10.1016/j.jaad.2011.02.026. View

13.

Grevelman E, Breed W . Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol. 2005; 16(3):352-8. DOI: 10.1093/annonc/mdi088. View

14.

Samuelov L, Sprecher E, Tsuruta D, Biro T, Kloepper J, Paus R . P-cadherin regulates human hair growth and cycling via canonical Wnt signaling and transforming growth factor-β2. J Invest Dermatol. 2012; 132(10):2332-2341. DOI: 10.1038/jid.2012.171. View

15.

Freedman T . Social and cultural dimensions of hair loss in women treated for breast cancer. Cancer Nurs. 1994; 17(4):334-41. View

16.

Clapham D . Calcium signaling. Cell. 2007; 131(6):1047-58. DOI: 10.1016/j.cell.2007.11.028. View

17.

Huelsken J, Vogel R, Erdmann B, Cotsarelis G, Birchmeier W . beta-Catenin controls hair follicle morphogenesis and stem cell differentiation in the skin. Cell. 2001; 105(4):533-45. DOI: 10.1016/s0092-8674(01)00336-1. View

18.

Munstedt K, Manthey N, Sachsse S, Vahrson H . Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997; 5(2):139-43. DOI: 10.1007/BF01262572. View

19.

De Jager P, Chibnik L, Cui J, Reischl J, Lehr S, Simon K . Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol. 2009; 8(12):1111-9. PMC: 3099419. DOI: 10.1016/S1474-4422(09)70275-3. View

20.

Trueb R . Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009; 28(1):11-4. DOI: 10.1016/j.sder.2008.12.001. View